Rui-Ping Dong

473 total citations
18 papers, 358 citations indexed

About

Rui-Ping Dong is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Rui-Ping Dong has authored 18 papers receiving a total of 358 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Immunology and 5 papers in Molecular Biology. Recurrent topics in Rui-Ping Dong's work include CAR-T cell therapy research (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Immunodeficiency and Autoimmune Disorders (2 papers). Rui-Ping Dong is often cited by papers focused on CAR-T cell therapy research (3 papers), Cancer Immunotherapy and Biomarkers (3 papers) and Immunodeficiency and Autoimmune Disorders (2 papers). Rui-Ping Dong collaborates with scholars based in China, Japan and United States. Rui-Ping Dong's co-authors include Stuart F. Schlossman, Chonghui Zhang, Jijie Gu, Hajime Tamai, Akinori Kimura, Mei X. Wu, Daniel F. McLaughlin, Deborah Marcellus, Sarah Mathews and Donna Reece and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Rui-Ping Dong

18 papers receiving 352 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rui-Ping Dong China 10 150 136 84 62 39 18 358
Eugene Tan United States 9 140 0.9× 103 0.8× 49 0.6× 83 1.3× 35 0.9× 20 413
Steve De Vos Belgium 7 98 0.7× 135 1.0× 87 1.0× 25 0.4× 46 1.2× 11 354
Sandra Sapia Argentina 9 78 0.5× 118 0.9× 69 0.8× 32 0.5× 35 0.9× 16 315
László Márkász Sweden 10 107 0.7× 184 1.4× 121 1.4× 62 1.0× 34 0.9× 23 379
Chia-Li Yu Taiwan 8 111 0.7× 98 0.7× 107 1.3× 51 0.8× 35 0.9× 11 334
Xiaoxiao Zuo China 11 260 1.7× 191 1.4× 80 1.0× 49 0.8× 16 0.4× 23 475
Yuhan Huang United States 9 262 1.7× 248 1.8× 44 0.5× 62 1.0× 32 0.8× 24 568
Suyu Miao China 8 256 1.7× 99 0.7× 41 0.5× 58 0.9× 33 0.8× 11 428
K Yamanaka Japan 8 104 0.7× 71 0.5× 66 0.8× 47 0.8× 14 0.4× 17 316

Countries citing papers authored by Rui-Ping Dong

Since Specialization
Citations

This map shows the geographic impact of Rui-Ping Dong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rui-Ping Dong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rui-Ping Dong more than expected).

Fields of papers citing papers by Rui-Ping Dong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rui-Ping Dong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rui-Ping Dong. The network helps show where Rui-Ping Dong may publish in the future.

Co-authorship network of co-authors of Rui-Ping Dong

This figure shows the co-authorship network connecting the top 25 collaborators of Rui-Ping Dong. A scholar is included among the top collaborators of Rui-Ping Dong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rui-Ping Dong. Rui-Ping Dong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Fukuoka, Masahiro, Seiji Yano, Giuseppe Giaccone, et al.. (2023). Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 41(6). 1162–1171. 7 indexed citations
2.
Ma, Cheng‐Ping, Yan Li, Rui-Ping Dong, et al.. (2023). Establishment and application of suspension static method in blood group screening of automated blood group analyzer. Scientific Reports. 13(1). 7564–7564. 1 indexed citations
3.
4.
Papadopoulos, Kyriakos P., Wael A. Harb, Cody J. Peer, et al.. (2021). First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors. The Oncologist. 26(9). e1514–e1525. 53 indexed citations
5.
Li, Lei, Min Huang, Leping Li, et al.. (2020). Abstract 3760: HH2710, a highly potent and selective erk1/2 inhibitor for the treatment of mapk mutant tumors. Cancer Research. 80(16_Supplement). 3760–3760. 3 indexed citations
6.
Shimizu, Toshio, Takako Eguchi Nakajima, WenLian Xu, et al.. (2019). Phase I safety and pharmacokinetic study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in Japanese patients with advanced solid tumors.. Journal of Clinical Oncology. 37(15_suppl). 2609–2609. 5 indexed citations
7.
Xu, Jianming, Shukui Qin, Yun Zhang, et al.. (2019). Phase I study of KN035, the first subcutaneously administered, novel fusion anti-PD-L1 antibody in patients with advanced solid tumors in China.. Journal of Clinical Oncology. 37(15_suppl). 2608–2608. 9 indexed citations
8.
9.
Dong, Rui-Ping, et al.. (2010). [Polymorphism of human killer cell immunoglobulin-like receptor gene in Chinese Jiangsu Han population].. PubMed. 18(3). 776–9. 2 indexed citations
10.
Kovacs, Michael J., Donna Reece, Deborah Marcellus, et al.. (2006). A phase II study of ZD6474 (Zactima™), a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma—NCIC CTG IND.145. Investigational New Drugs. 24(6). 529–535. 60 indexed citations
11.
12.
Yano, Seiichi, Motonori Yamaguchi, & Rui-Ping Dong. (2003). EGFR tyrosine kinase inhibitor "gefitinib (Iressa)" for cancer therapy.. Folia Pharmacologica Japonica. 122(6). 491–497. 17 indexed citations
13.
Gu, Jijie, Rui-Ping Dong, Chonghui Zhang, et al.. (1999). Functional Interaction of DFF35 and DFF45 with Caspase-activated DNA Fragmentation Nuclease DFF40. Journal of Biological Chemistry. 274(30). 20759–20762. 72 indexed citations
14.
Dong, Rui-Ping, et al.. (1997). Different Regulatory Effects of Pentoxifylline on Human T Cell Activation Pathways. Journal of Clinical Immunology. 17(3). 247–252. 16 indexed citations
15.
Hegen, Martin, Junichi Kameoka, Rui-Ping Dong, Chikao Morimoto, & S F Schlossman. (1997). Structure of CD26 (Dipeptidyl Peptidase IV) and Function in Human T Cell Activation. Advances in experimental medicine and biology. 421. 109–116. 17 indexed citations
16.
Kimura, Akinori, et al.. (1995). HLA-A and -DRB4 genes in controlling the susceptibility to Hashimoto's thyroiditis. Human Immunology. 42(2). 131–136. 42 indexed citations
17.
Kimura, Akinori, et al.. (1993). Immunogenetic Analysis of Silicosis in Japan. American Journal of Respiratory Cell and Molecular Biology. 8(1). 106–111. 33 indexed citations
18.
Harada, Haruhito, et al.. (1992). Sequencing and population analysis of four novel HLA-DPA1 alleles. Human Immunology. 35(3). 173–178. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eugene Tan Breakdown of academic impact, for papers by Steve De Vos Breakdown of academic impact, for papers by Sandra Sapia Breakdown of academic impact, for papers by László Márkász Breakdown of academic impact, for papers by Chia-Li Yu Breakdown of academic impact, for papers by Xiaoxiao Zuo Breakdown of academic impact, for papers by Yuhan Huang Breakdown of academic impact, for papers by Suyu Miao Breakdown of academic impact, for papers by K Yamanaka
Rankless by CCL
2026